Zogenix, Inc. (NASDAQ:ZGNX) Director Renee P. Tannenbaum bought 5,000 shares of Zogenix stock in a transaction that occurred on Thursday, March 16th. The shares were acquired at an average cost of $11.00 per share, for a total transaction of $55,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $110,000. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of Zogenix, Inc. (NASDAQ:ZGNX) traded down 1.40% on Monday, hitting $10.55. The stock had a trading volume of 196,430 shares. Zogenix, Inc. has a 12-month low of $7.33 and a 12-month high of $13.70. The company’s market cap is $261.78 million. The stock has a 50 day moving average price of $9.71 and a 200-day moving average price of $10.38.
Your IP Address:
ZGNX has been the topic of several recent analyst reports. Aegis reaffirmed a “buy” rating and set a $28.00 target price on shares of Zogenix in a research report on Saturday, March 11th. Zacks Investment Research raised Zogenix from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Thursday, January 12th.
A number of hedge funds have recently made changes to their positions in ZGNX. A.R.T. Advisors LLC acquired a new stake in shares of Zogenix during the fourth quarter worth about $154,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Zogenix during the third quarter worth about $169,000. Cadian Capital Management LP increased its stake in shares of Zogenix by 30.5% in the third quarter. Cadian Capital Management LP now owns 192,500 shares of the company’s stock worth $2,200,000 after buying an additional 45,000 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Zogenix by 101.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 216,814 shares of the company’s stock worth $2,634,000 after buying an additional 109,134 shares during the period. Finally, City Financial Investment Co Ltd acquired a new stake in shares of Zogenix during the fourth quarter worth about $1,393,000. 84.32% of the stock is owned by institutional investors.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with our FREE daily email newsletter.